NCT03343678 is a Phase 1 clinical trial of Venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT03343678?

NCT03343678 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT03343678?

Interventions in NCT03343678: Venetoclax, BI 836826.

What condition does NCT03343678 study?

NCT03343678 studies Leukemia, Lymphocytic, Chronic, B-Cell.

Is NCT03343678 still recruiting?

NCT03343678 is currently withdrawn. Last updated 9 January 2018.

Last reviewed 2018-01-09 · How we verify

NCT03343678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

Withdrawn Phase 1 Last updated 9 January 2018

What this trial tests

Phase 1 trial testing Venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell. Withdrawn.

Timeline

17 January 2018

Primary endpoint
25 May 2018

25 November 2020

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Design	parallel
Masking	none
Primary purpose	treatment
Start date	17 January 2018
Primary completion	25 May 2018
Estimated completion	25 November 2020

Drugs / interventions tested

Venetoclax (venetoclax) — full drug profile →
BI 836826

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell — all drugs for Leukemia, Lymphocytic, Chronic, B-Cell →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

18 and older, any sex, with Leukemia, Lymphocytic, Chronic, B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this trial is to determine the maximum tolerated dose (MTD) of BI 836826 in combination with venetoclax on the basis of dose limiting toxicities (DLTs incidence rate during the MTD evaluation period of the combination treatment and to determine the recommended Phase II dose (RP2D) of the combination. Other objectives are to evaluate the pharmacokinetics of BI 836826 in combination with venetoclax and to further determine the safety, as well as to evaluate the efficacy of the combination by means of the Complete Response (CR) rate and Minimal Residual Disease (MRD) negativity rate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Venetoclax

Trials testing the same drug.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting

Other recruiting trials for Leukemia, Lymphocytic, Chronic, B-Cell

Currently open trials in the same condition.

NCT06364423 — Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias · Phase 1, PHASE2 · recruiting
NCT05963074 — A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemi · Phase 2 · recruiting
NCT06299540 — Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lym · recruiting
NCT05947851 — A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) · Phase 3 · recruiting
NCT05424822 — A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin · Phase 1 · active not recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03343678 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 9 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03343678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing